Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Accelerating the Development of Next Generation Bioconjugate Drugs Through an Integrated Platform

Accelerating the Development of Next Generation Bioconjugate Drugs Through an Integrated Platform

12:30 pm - Tuesday 13th October 2026

Overviewing the challenges in bioconjugation CMC development for novel NDCs
Case study examples: Exploring strategies and fit for purpose solutions for complex bioconjugation processes development
Overviewing AsymChem/ AsymBio’s integrated capabilities in NDC CDMO services

Speakers:

Tiejun Li

Tiejun Li

Vice General Manager

Asymchem Laboratories (Tianjin) Co., Ltd